Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has achieved a significant milestone by surpassing two million Motiva Implants in the market. This achievement reflects a steady growth trajectory, with the company delivering one million implants in the first seven years and doubling that in just two years. The implants maintain an impressive less than 1% clinical complication rate, showcasing their safety and effectiveness. Operating in over 80 countries, Establishment Labs is committed to innovation in breast aesthetics and reconstruction, aiming to raise standards in women's health.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for the quarter ending December 31, 2021, on March 1, 2022, before market opens. The company will host a conference call at 8:30 am ET the same day to discuss these results. Established in 2010, the company focuses on women’s health, particularly breast aesthetics and reconstruction, offering innovative silicone gel-filled Motiva Implants®. Over 2 million of these implants have been distributed across 80 countries, emphasizing its global presence and commitment to advanced healthcare solutions.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported preliminary unaudited revenue for Q4 2021 expected between $35.0 million and $35.5 million, signifying a growth of 30% to 32% year-over-year. For the fiscal year 2021, the company anticipates revenue of $126.4 million to $126.9 million, reflecting a growth of 49% to 50% compared to 2020. The company will share its complete financial results on March 1, 2022.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global leader in women's health technology, has announced that CEO Juan José Chacón-Quirós will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative Motiva Implants with over 1.8 million units delivered since 2010 across 80 countries.
Establishment Labs (NASDAQ: ESTA) has appointed Raj Denhoy as Chief Financial Officer, effective immediately. Denhoy, who joined the company in February 2021 and served as Interim CFO since August, has extensive experience in medical device research. CEO Juan José Chacón-Quirós highlighted Denhoy's understanding of the business and industry vision. Denhoy expressed optimism about the company's potential to lead in breast aesthetics and reconstruction, emphasizing innovation and stakeholder value.
Establishment Labs Holdings (NASDAQ: ESTA) announced the immediate appointment of Leslie Gillin to its Board of Directors, bringing extensive experience in consumer marketing and finance. CEO Juan José Chacón-Quirós expressed confidence in Gillin's ability to enhance patient engagement and innovative business models. Gillin, formerly of JPMorgan Chase and Citibank, aims to leverage the company’s unique technologies for improved patient experiences and expanded market presence. Established in 2010, Establishment Labs focuses on breast health with over 1.8 million Motiva Implants® sold globally.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Stephens Annual Investment Conference from December 1-3, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will speak on December 2 at 1:00 pm CT. The presentation will be available via live webcast on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women's health, providing innovative breast aesthetics solutions, including its Motiva Implants, with over 1.8 million units delivered since 2010.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in two investment conferences. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will attend the Jefferies London Healthcare Conference on November 16, 2021, and the Canaccord Genuity Virtual MedTech Forum on November 18, 2021. Live webcasts of their presentations will be available on the Establishment Labs investor relations website, with archived versions accessible afterward. The company specializes in breast aesthetics and reconstruction, offering innovative silicone gel-filled implants globally.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported third-quarter 2021 revenue of $29.0 million, up 27.6% year-over-year. Gross profit margin improved to 67.6%, while operating expenses increased to $28.7 million, driven by a return to normal business conditions. The company raised its 2021 revenue guidance to $124 million to $128 million, a growth of 46% to 51% over 2020. A net loss of $9.0 million was recorded. The company launched the Motiva Flora® tissue expander, and its Motiva implants are on track for U.S. and China market entry.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Jeffrey Bettinger as Global Head of People. Bettinger, previously Chief People and Places Officer at Nu Skin, joins the executive team with a focus on culture and human capital strategy. CEO Juan José Chacón-Quirós emphasized the importance of people and culture for the company's upcoming growth and global expansion. Measuring past success in leadership development, Bettinger aims to innovate within the Femtech industry to positively impact women's lives. Establishment Labs specializes in breast aesthetics and has delivered over 1.8 million Motiva Implants in 80+ countries.